Skip to content

NGEN

NervGen Pharma Corp.

NASDAQ · Healthcare · Biotechnology · CA

$1.54
−3.14%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
+49.3%
EBIT
-68.6%
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
+51.9%

Three-year CAGR

Revenue
—
EBITDA
+76.4%
EBIT
-0.7%
Net income
-83.9%
EPS
-69.4%
Free cash flow
-15.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026